Results of the phase 3 clinical trial of ADI-PEG20 (pergargiminase) combined with chemotherapy
Posted on 02/17/2024 at 8.31pm Posted on 02/17/2024 at 8.31pm Views 0
Mesothelioma, which affects thousands of patients worldwide every year, develops mainly in the lungs of people exposed to asbestos and is notoriously aggressive and deadly, with a low survival rate. [사진=게티이미지뱅크]There is an incurable cancer for which asbestos is the main causative agent. Mesothelioma is a malignant tumor that occurs in the mesothelium, a thin layer of tissue that covers organs such as the lungs.
A new drug has been developed that quadruples the survival rate of mesothelioma patients. Based on an article by researchers from Queen Mary University of London (QMUL) published in the Journal of the American Medical Association (JAMA Oncology) on the 15th (local time), the Guardian reported that the biggest breakthrough in 20 years has been achieved years.
Mesothelioma, which affects thousands of patients worldwide every year, develops mainly in the lungs of people exposed to asbestos and is notoriously aggressive and deadly, with a low survival rate. The research team led by Professor Peter Schlosarek of QMUL combined a new drug called ADI-PEG20 (pergargiminase) with chemotherapy and conducted a clinical trial on 249 people in 5 countries, consequently increasing the 3-year survival rate of patients suffering from mesothelioma. four times I reported that I ordered it.
Researchers conducted a clinical study on patients with pleural mesothelioma (mesothelioma that occurs in the pleura covering the lungs) registered at 43 medical centers in five countries: UK, US, Australia, Italy and Taiwan between 2017 and 2021. Participants, with an average age of 70, received up to six cycles of chemotherapy every three weeks. Half received the new drug and the other half received a placebo for two years.
People who received pegargiminase and chemotherapy survived for an average of 9.3 months. Survival time for the control group that received placebo and chemotherapy was 7.7 months. “Progression-free survival,” in which cancer cells no longer spread, was 6.2 months for pegargiminase chemotherapy. Survival time in the placebo group was 5.6 months.
The researchers said: “In a phase 3 study of 249 patients with pleural mesothelioma, pegargiminase chemotherapy significantly increased median overall survival by 1.6 months compared to placebo chemotherapy, and increased it by four-fold if continued for 36 months”. An 80-year-old participant who developed mesothelioma due to exposure to asbestos in a factory in the 1970s was told he only had four months to live, but is still alive five years after taking part in the clinical trial .
This breakthrough is the result of 20 years of research by Professor Schlosarek, who first discovered that mesothelioma cells lack a protein called ASS1, which allows cells to produce the amino acid arginine. ADI-PEG20, developed based on this, reduces arginine levels in the blood. For cancer cells that are unable to produce arginine on their own, this means that their growth is hindered.
Professor Schlosarek said: “This research result is something I have pursued in my laboratory since the beginning,” and added: “It is truly wonderful to see research into arginine deficiency in cancer cells coming to fruition.” Polaris Group, an American biotechnology company that supported this research, and Cancer Research UK (CRUK) hope the newly developed treatment will become the standard treatment for mesothelioma.
The document can be found at the following link:
“Copyright ⓒ ‘Honest Knowledge for Health’ Comedy.com ( / Unauthorized reproduction and redistribution, AI learning and use prohibited”
#drug #released #quadruples #3year #survival #rate #mesothelioma #patients
